Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): Fragmin (02132664). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Dalteparin sodium
Form:
10 of 10 products shown
All strengths: Limited Use, Reason for Use code 186, 187, 188, 189 required; same patient cost rules
Shared coverage and patient cost rules
StatusLimited Use, Reason for Use code 186, 187, 188, 189 required
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Fragmin · DIN 02132621 · 2500 IU/0.2 mL · injection, pre-filled syringe
Limited Use, Reason for Use code 186, 187, 188, 189 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 186 or 187 or 188 or 189 (criteria below)
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria, code 186, 187, 188, 189
Reason for Use code 186
For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 187
For DVT in pregnant or lactating females;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 188
For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 189
For DVT in patients who have failed treatment with warfarin.
Coverage limit:
LU Authorization Period: 1 year
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Dalteparin
Brand(s): Fragmin
DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products
For peri-operative bridging for patients who require long-term warfarin therapy and must
temporarily discontinue it before and after surgery, and who are at moderate- to high-risk
for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the date
of surgery plus up to 7 days after surgery.
For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on the
day of surgery.
For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or risk
factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days
For extended treatment of symptomatic acute venous thromboembolism (VTE) in
patients with cancer for whom warfarin treatment is not appropriate on a case-by-case
basis.
Standard Approval Duration: 6 months
28
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 28, record 7, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Dalteparin
Brand(s): Fragmin
DOSAGE FORM/ STRENGTH: Check e-formulary for funded strengths
1. For peri-operative bridging for patients who require long-term warfarin therapy and
must temporarily discontinue it before and after surgery, and who are at moderate- to
high-risk for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the
date of surgery plus up to 7 days after the date of hospital discharge
2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on
the day of surgery
3. For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or
risk factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days.
4. For extended treatment of symptomatic acute venous thromboembolism (VTE)
in patients with cancer, who cannot use warfarin.
Standard Approval Duration: As requested up to 6 months
469
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 469, record 308, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
No interchangeable product listed in the Ontario extract
Fragmin · DIN 02132621
Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01
Health Canada: Marketed since 2005-07-12 · brand FRAGMIN · ATC B01AB04 DALTEPARIN · form Solution · route Subcutaneous, Intravenous · ingredients DALTEPARIN SODIUM 2500 UNIT/0.2ML · company Pfizer canada ulc · schedule Prescription
DIN 02132621: Fragmin
Raw flags: sec12=Y, sec3=Y
Item: 201200038; group id 253; item number 0450; lccId 00045; manufacturer id PFI
Source form: Inj Pref Syr; strength: 2500IU/0.2mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $6.0498; ministry $6.0498
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02132621
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18307
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02132621
Shortage record checked October 6, 2026
Fragmin · DIN 02430789 · 3500 IU/0.28 mL · injection, pre-filled syringe
Limited Use, Reason for Use code 186, 187, 188, 189 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 186 or 187 or 188 or 189 (criteria below)
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria, code 186, 187, 188, 189
Reason for Use code 186
For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 187
For DVT in pregnant or lactating females;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 188
For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 189
For DVT in patients who have failed treatment with warfarin.
Coverage limit:
LU Authorization Period: 1 year
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Dalteparin
Brand(s): Fragmin
DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products
For peri-operative bridging for patients who require long-term warfarin therapy and must
temporarily discontinue it before and after surgery, and who are at moderate- to high-risk
for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the date
of surgery plus up to 7 days after surgery.
For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on the
day of surgery.
For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or risk
factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days
For extended treatment of symptomatic acute venous thromboembolism (VTE) in
patients with cancer for whom warfarin treatment is not appropriate on a case-by-case
basis.
Standard Approval Duration: 6 months
28
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 28, record 7, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Dalteparin
Brand(s): Fragmin
DOSAGE FORM/ STRENGTH: Check e-formulary for funded strengths
1. For peri-operative bridging for patients who require long-term warfarin therapy and
must temporarily discontinue it before and after surgery, and who are at moderate- to
high-risk for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the
date of surgery plus up to 7 days after the date of hospital discharge
2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on
the day of surgery
3. For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or
risk factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days.
4. For extended treatment of symptomatic acute venous thromboembolism (VTE)
in patients with cancer, who cannot use warfarin.
Standard Approval Duration: As requested up to 6 months
469
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 469, record 308, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
No interchangeable product listed in the Ontario extract
Fragmin · DIN 02430789
Manufacturer: Pfizer Canada Inc.; listing date 2016-03-30
Health Canada: Marketed since 2015-03-25 · brand FRAGMIN · ATC B01AB04 DALTEPARIN · form Solution · route Subcutaneous, Intravenous · ingredients DALTEPARIN SODIUM 3500 UNIT/0.28ML · company Pfizer canada ulc · schedule Prescription
DIN 02430789: Fragmin
Raw flags: sec12=Y, sec3=Y
Item: 201200099; group id 253; item number 0448; lccId 00045; manufacturer id PFI
Source form: Inj Pref Syr; strength: 3500IU/0.28mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $8.4689; ministry $8.4689
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02430789
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91522
Shortage status: resolved shortage (ended May 7, 2019); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02430789
Shortage record checked October 6, 2026
Fragmin · DIN 02132648 · 5000 IU/0.2 mL · injection, pre-filled syringe
Limited Use, Reason for Use code 186, 187, 188, 189 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 186 or 187 or 188 or 189 (criteria below)
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria, code 186, 187, 188, 189
Reason for Use code 186
For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 187
For DVT in pregnant or lactating females;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 188
For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 189
For DVT in patients who have failed treatment with warfarin.
Coverage limit:
LU Authorization Period: 1 year
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Dalteparin
Brand(s): Fragmin
DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products
For peri-operative bridging for patients who require long-term warfarin therapy and must
temporarily discontinue it before and after surgery, and who are at moderate- to high-risk
for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the date
of surgery plus up to 7 days after surgery.
For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on the
day of surgery.
For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or risk
factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days
For extended treatment of symptomatic acute venous thromboembolism (VTE) in
patients with cancer for whom warfarin treatment is not appropriate on a case-by-case
basis.
Standard Approval Duration: 6 months
28
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 28, record 7, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Dalteparin
Brand(s): Fragmin
DOSAGE FORM/ STRENGTH: Check e-formulary for funded strengths
1. For peri-operative bridging for patients who require long-term warfarin therapy and
must temporarily discontinue it before and after surgery, and who are at moderate- to
high-risk for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the
date of surgery plus up to 7 days after the date of hospital discharge
2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on
the day of surgery
3. For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or
risk factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days.
4. For extended treatment of symptomatic acute venous thromboembolism (VTE)
in patients with cancer, who cannot use warfarin.
Standard Approval Duration: As requested up to 6 months
469
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 469, record 308, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
No interchangeable product listed in the Ontario extract
Fragmin · DIN 02132648
Manufacturer: Pfizer Canada Inc.; listing date 1997-04-10
Health Canada: Marketed since 2005-05-03 · brand FRAGMIN · ATC B01AB04 DALTEPARIN · form Solution · route Subcutaneous, Intravenous · ingredients DALTEPARIN SODIUM 5000 UNIT/0.2ML · company Pfizer canada ulc · schedule Prescription
DIN 02132648: Fragmin
Raw flags: sec12=Y, sec3=Y
Item: 201200040; group id 253; item number 0451; lccId 00045; manufacturer id PFI
Source form: Inj Pref Syr; strength: 5000IU/0.2mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $12.0996; ministry $12.0996
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02132648
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18306
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02132648
Shortage record checked October 6, 2026
Fragmin · DIN 02352648 · 7500 IU/0.3 mL · injection, pre-filled syringe
Limited Use, Reason for Use code 186, 187, 188, 189 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 186 or 187 or 188 or 189 (criteria below)
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria, code 186, 187, 188, 189
Reason for Use code 186
For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 187
For DVT in pregnant or lactating females;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 188
For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 189
For DVT in patients who have failed treatment with warfarin.
Coverage limit:
LU Authorization Period: 1 year
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Dalteparin
Brand(s): Fragmin
DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products
For peri-operative bridging for patients who require long-term warfarin therapy and must
temporarily discontinue it before and after surgery, and who are at moderate- to high-risk
for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the date
of surgery plus up to 7 days after surgery.
For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on the
day of surgery.
For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or risk
factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days
For extended treatment of symptomatic acute venous thromboembolism (VTE) in
patients with cancer for whom warfarin treatment is not appropriate on a case-by-case
basis.
Standard Approval Duration: 6 months
28
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 28, record 7, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Dalteparin
Brand(s): Fragmin
DOSAGE FORM/ STRENGTH: Check e-formulary for funded strengths
1. For peri-operative bridging for patients who require long-term warfarin therapy and
must temporarily discontinue it before and after surgery, and who are at moderate- to
high-risk for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the
date of surgery plus up to 7 days after the date of hospital discharge
2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on
the day of surgery
3. For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or
risk factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days.
4. For extended treatment of symptomatic acute venous thromboembolism (VTE)
in patients with cancer, who cannot use warfarin.
Standard Approval Duration: As requested up to 6 months
469
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 469, record 308, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
No interchangeable product listed in the Ontario extract
Fragmin · DIN 02352648
Manufacturer: Pfizer Canada Inc.; listing date 2012-02-29
Health Canada: Marketed since 2011-02-01 · brand FRAGMIN · ATC B01AB04 DALTEPARIN · form Solution · route Intravenous, Subcutaneous · ingredients DALTEPARIN SODIUM 7500 UNIT/0.3ML · company Pfizer canada ulc · schedule Prescription
DIN 02352648: Fragmin
Raw flags: sec12=Y, sec3=Y
Item: 201200083; group id 253; item number 0449; lccId 00045; manufacturer id PFI
Source form: Inj Pref Syr; strength: 7500IU/0.3mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $18.1504; ministry $18.1504
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02352648
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83790
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02352648
Shortage record checked October 6, 2026
Fragmin · DIN 02352656 · 10000 IU/0.4 mL · injection, pre-filled syringe
Limited Use, Reason for Use code 186, 187, 188, 189 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 186 or 187 or 188 or 189 (criteria below)
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria, code 186, 187, 188, 189
Reason for Use code 186
For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 187
For DVT in pregnant or lactating females;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 188
For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 189
For DVT in patients who have failed treatment with warfarin.
Coverage limit:
LU Authorization Period: 1 year
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Dalteparin
Brand(s): Fragmin
DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products
For peri-operative bridging for patients who require long-term warfarin therapy and must
temporarily discontinue it before and after surgery, and who are at moderate- to high-risk
for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the date
of surgery plus up to 7 days after surgery.
For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on the
day of surgery.
For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or risk
factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days
For extended treatment of symptomatic acute venous thromboembolism (VTE) in
patients with cancer for whom warfarin treatment is not appropriate on a case-by-case
basis.
Standard Approval Duration: 6 months
28
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 28, record 7, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Dalteparin
Brand(s): Fragmin
DOSAGE FORM/ STRENGTH: Check e-formulary for funded strengths
1. For peri-operative bridging for patients who require long-term warfarin therapy and
must temporarily discontinue it before and after surgery, and who are at moderate- to
high-risk for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the
date of surgery plus up to 7 days after the date of hospital discharge
2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on
the day of surgery
3. For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or
risk factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days.
4. For extended treatment of symptomatic acute venous thromboembolism (VTE)
in patients with cancer, who cannot use warfarin.
Standard Approval Duration: As requested up to 6 months
469
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 469, record 308, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
No interchangeable product listed in the Ontario extract
Fragmin · DIN 02352656
Manufacturer: Pfizer Canada Inc.; listing date 2011-03-15
Health Canada: Marketed since 2011-02-01 · brand FRAGMIN · ATC B01AB04 DALTEPARIN · form Solution · route Intravenous, Subcutaneous · ingredients DALTEPARIN SODIUM 10000 UNIT/0.4ML · company Pfizer canada ulc · schedule Prescription
DIN 02352656: Fragmin
Raw flags: sec12=Y, sec3=Y
Item: 201200064; group id 253; item number 0452; lccId 00045; manufacturer id PFI
Source form: Inj Pref Syr; strength: 10000IU/0.4mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $24.2012; ministry $24.2012
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02352656
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83791
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02352656
Shortage record checked October 6, 2026
Fragmin · DIN 02352664 · 12500 IU/0.5 mL · injection, pre-filled syringe
Limited Use, Reason for Use code 186, 187, 188, 189 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 186 or 187 or 188 or 189 (criteria below)
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria, code 186, 187, 188, 189
Reason for Use code 186
For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 187
For DVT in pregnant or lactating females;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 188
For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 189
For DVT in patients who have failed treatment with warfarin.
Coverage limit:
LU Authorization Period: 1 year
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Dalteparin
Brand(s): Fragmin
DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products
For peri-operative bridging for patients who require long-term warfarin therapy and must
temporarily discontinue it before and after surgery, and who are at moderate- to high-risk
for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the date
of surgery plus up to 7 days after surgery.
For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on the
day of surgery.
For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or risk
factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days
For extended treatment of symptomatic acute venous thromboembolism (VTE) in
patients with cancer for whom warfarin treatment is not appropriate on a case-by-case
basis.
Standard Approval Duration: 6 months
28
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 28, record 7, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Dalteparin
Brand(s): Fragmin
DOSAGE FORM/ STRENGTH: Check e-formulary for funded strengths
1. For peri-operative bridging for patients who require long-term warfarin therapy and
must temporarily discontinue it before and after surgery, and who are at moderate- to
high-risk for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the
date of surgery plus up to 7 days after the date of hospital discharge
2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on
the day of surgery
3. For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or
risk factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days.
4. For extended treatment of symptomatic acute venous thromboembolism (VTE)
in patients with cancer, who cannot use warfarin.
Standard Approval Duration: As requested up to 6 months
469
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 469, record 308, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
No interchangeable product listed in the Ontario extract
Fragmin · DIN 02352664
Manufacturer: Pfizer Canada Inc.; listing date 2011-03-15
Health Canada: Marketed since 2011-02-01 · brand FRAGMIN · ATC B01AB04 DALTEPARIN · form Solution · route Subcutaneous, Intravenous · ingredients DALTEPARIN SODIUM 12500 UNIT/0.5ML · company Pfizer canada ulc · schedule Prescription
DIN 02352664: Fragmin
Raw flags: sec12=Y, sec3=Y
Item: 201200065; group id 253; item number 0453; lccId 00045; manufacturer id PFI
Source form: Inj Pref Syr; strength: 12500IU/0.5mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $30.2520; ministry $30.2520
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02352664
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83792
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02352664
Shortage record checked October 6, 2026
Fragmin · DIN 02352672 · 15000 IU/0.6 mL · injection, pre-filled syringe
Limited Use, Reason for Use code 186, 187, 188, 189 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 186 or 187 or 188 or 189 (criteria below)
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria, code 186, 187, 188, 189
Reason for Use code 186
For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 187
For DVT in pregnant or lactating females;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 188
For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 189
For DVT in patients who have failed treatment with warfarin.
Coverage limit:
LU Authorization Period: 1 year
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Dalteparin
Brand(s): Fragmin
DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products
For peri-operative bridging for patients who require long-term warfarin therapy and must
temporarily discontinue it before and after surgery, and who are at moderate- to high-risk
for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the date
of surgery plus up to 7 days after surgery.
For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on the
day of surgery.
For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or risk
factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days
For extended treatment of symptomatic acute venous thromboembolism (VTE) in
patients with cancer for whom warfarin treatment is not appropriate on a case-by-case
basis.
Standard Approval Duration: 6 months
28
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 28, record 7, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Dalteparin
Brand(s): Fragmin
DOSAGE FORM/ STRENGTH: Check e-formulary for funded strengths
1. For peri-operative bridging for patients who require long-term warfarin therapy and
must temporarily discontinue it before and after surgery, and who are at moderate- to
high-risk for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the
date of surgery plus up to 7 days after the date of hospital discharge
2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on
the day of surgery
3. For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or
risk factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days.
4. For extended treatment of symptomatic acute venous thromboembolism (VTE)
in patients with cancer, who cannot use warfarin.
Standard Approval Duration: As requested up to 6 months
469
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 469, record 308, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
No interchangeable product listed in the Ontario extract
Fragmin · DIN 02352672
Manufacturer: Pfizer Canada Inc.; listing date 2011-03-15
Health Canada: Marketed since 2011-02-01 · brand FRAGMIN · ATC B01AB04 DALTEPARIN · form Solution · route Subcutaneous, Intravenous · ingredients DALTEPARIN SODIUM 15000 UNIT/0.6ML · company Pfizer canada ulc · schedule Prescription
DIN 02352672: Fragmin
Raw flags: sec12=Y, sec3=Y
Item: 201200066; group id 253; item number 0454; lccId 00045; manufacturer id PFI
Source form: Inj Pref Syr; strength: 15000IU/0.6mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $36.2927; ministry $36.2927
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02352672
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83793
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02352672
Shortage record checked October 6, 2026
Fragmin · DIN 02494582 · 16500 IU/0.66 mL · injection, pre-filled syringe-0.66mL Pk
Limited Use, Reason for Use code 186, 187, 188, 189 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 186 or 187 or 188 or 189 (criteria below)
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria, code 186, 187, 188, 189
Reason for Use code 186
For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 187
For DVT in pregnant or lactating females;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 188
For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 189
For DVT in patients who have failed treatment with warfarin.
Coverage limit:
LU Authorization Period: 1 year
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Dalteparin
Brand(s): Fragmin
DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products
For peri-operative bridging for patients who require long-term warfarin therapy and must
temporarily discontinue it before and after surgery, and who are at moderate- to high-risk
for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the date
of surgery plus up to 7 days after surgery.
For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on the
day of surgery.
For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or risk
factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days
For extended treatment of symptomatic acute venous thromboembolism (VTE) in
patients with cancer for whom warfarin treatment is not appropriate on a case-by-case
basis.
Standard Approval Duration: 6 months
28
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 28, record 7, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Dalteparin
Brand(s): Fragmin
DOSAGE FORM/ STRENGTH: Check e-formulary for funded strengths
1. For peri-operative bridging for patients who require long-term warfarin therapy and
must temporarily discontinue it before and after surgery, and who are at moderate- to
high-risk for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the
date of surgery plus up to 7 days after the date of hospital discharge
2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on
the day of surgery
3. For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or
risk factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days.
4. For extended treatment of symptomatic acute venous thromboembolism (VTE)
in patients with cancer, who cannot use warfarin.
Standard Approval Duration: As requested up to 6 months
469
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 469, record 308, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
No interchangeable product listed in the Ontario extract
Fragmin · DIN 02494582
Manufacturer: Pfizer Canada Inc.; listing date 2021-02-26
Health Canada: Marketed since 2020-06-08 · brand FRAGMIN · ATC B01AB04 DALTEPARIN · form Solution · route Subcutaneous, Intravenous · ingredients DALTEPARIN SODIUM 16500 UNIT/0.66ML · company Pfizer canada ulc · schedule Prescription
DIN 02494582: Fragmin
Raw flags: sec12=Y, sec3=Y
Item: 201200105; group id 253; item number 0456; lccId 00045; manufacturer id PFI
Source form: Inj Pref Syr-0.66mL Pk; strength: 16500IU/0.66mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $39.9223; ministry $39.9223
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02494582
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98458
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02494582
Shortage record checked October 6, 2026
Fragmin · DIN 02352680 · 18000 IU/0.72 mL · injection, pre-filled syringe
Limited Use, Reason for Use code 186, 187, 188, 189 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 186 or 187 or 188 or 189 (criteria below)
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria, code 186, 187, 188, 189
Reason for Use code 186
For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 187
For DVT in pregnant or lactating females;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 188
For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 189
For DVT in patients who have failed treatment with warfarin.
Coverage limit:
LU Authorization Period: 1 year
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Dalteparin
Brand(s): Fragmin
DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products
For peri-operative bridging for patients who require long-term warfarin therapy and must
temporarily discontinue it before and after surgery, and who are at moderate- to high-risk
for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the date
of surgery plus up to 7 days after surgery.
For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on the
day of surgery.
For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or risk
factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days
For extended treatment of symptomatic acute venous thromboembolism (VTE) in
patients with cancer for whom warfarin treatment is not appropriate on a case-by-case
basis.
Standard Approval Duration: 6 months
28
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 28, record 7, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Dalteparin
Brand(s): Fragmin
DOSAGE FORM/ STRENGTH: Check e-formulary for funded strengths
1. For peri-operative bridging for patients who require long-term warfarin therapy and
must temporarily discontinue it before and after surgery, and who are at moderate- to
high-risk for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the
date of surgery plus up to 7 days after the date of hospital discharge
2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on
the day of surgery
3. For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or
risk factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days.
4. For extended treatment of symptomatic acute venous thromboembolism (VTE)
in patients with cancer, who cannot use warfarin.
Standard Approval Duration: As requested up to 6 months
469
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 469, record 308, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
No interchangeable product listed in the Ontario extract
Fragmin · DIN 02352680
Manufacturer: Pfizer Canada Inc.; listing date 2011-03-15
Health Canada: Marketed since 2011-02-01 · brand FRAGMIN · ATC B01AB04 DALTEPARIN · form Solution · route Subcutaneous, Intravenous · ingredients DALTEPARIN SODIUM 18000 UNIT/0.72ML · company Pfizer canada ulc · schedule Prescription
DIN 02352680: Fragmin
Raw flags: sec12=Y, sec3=Y
Item: 201200067; group id 253; item number 0455; lccId 00045; manufacturer id PFI
Source form: Inj Pref Syr; strength: 18000IU/0.72mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $43.5520; ministry $43.5520
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02352680
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83794
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02352680
Limited Use, Reason for Use code 186, 187, 188, 189 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 186 or 187 or 188 or 189 (criteria below)
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria, code 186, 187, 188, 189
Reason for Use code 186
For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 187
For DVT in pregnant or lactating females;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 188
For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 189
For DVT in patients who have failed treatment with warfarin.
Coverage limit:
LU Authorization Period: 1 year
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Dalteparin
Brand(s): Fragmin
DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products
For peri-operative bridging for patients who require long-term warfarin therapy and must
temporarily discontinue it before and after surgery, and who are at moderate- to high-risk
for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the date
of surgery plus up to 7 days after surgery.
For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on the
day of surgery.
For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or risk
factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days
For extended treatment of symptomatic acute venous thromboembolism (VTE) in
patients with cancer for whom warfarin treatment is not appropriate on a case-by-case
basis.
Standard Approval Duration: 6 months
28
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 28, record 7, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Dalteparin
Brand(s): Fragmin
DOSAGE FORM/ STRENGTH: Check e-formulary for funded strengths
1. For peri-operative bridging for patients who require long-term warfarin therapy and
must temporarily discontinue it before and after surgery, and who are at moderate- to
high-risk for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the
date of surgery plus up to 7 days after the date of hospital discharge
2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on
the day of surgery
3. For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or
risk factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days.
4. For extended treatment of symptomatic acute venous thromboembolism (VTE)
in patients with cancer, who cannot use warfarin.
Standard Approval Duration: As requested up to 6 months
469
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 469, record 308, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
No interchangeable product listed in the Ontario extract
Fragmin · DIN 02231171
Manufacturer: Pfizer Canada Inc.; listing date 1998-12-31
Health Canada: Marketed since 2005-05-20 · brand FRAGMIN · ATC B01AB04 DALTEPARIN · form Solution · route Intravenous, Subcutaneous · ingredients DALTEPARIN SODIUM 25000 UNIT/ML · company Pfizer canada ulc · schedule Prescription
DIN 02231171: Fragmin
Raw flags: sec12=Y, sec3=Y
Item: 201200043; group id 253; item number 0457; lccId 00045; manufacturer id PFI
Source form: Multidose 3.8mL Pk; strength: 25000IU/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $181.4839; ministry $181.4839
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02231171
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50478
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02231171
Shortage record checked October 6, 2026
Other products in the same Health Canada class (B01A, B01AB): coverage varies; not interchangeable
Enoxaparin (Noromby): general benefit
Nadroparin (Fraxiparine): limited Use 186, 187, 188, 189
Tinzaparin (Innohep): limited Use 186, 187, 188, 189, 323
Apixaban (Eliquis): general benefit
Dabigatran etexilate (Pradaxa): general benefit, not a benefit
Edoxaban (Lixiana): general benefit
5 more in the class list below
Other drugs in the same formulary class (20:12 Coagulants and Anti-Coagulants) and how they are covered
Matched class: 20:12 Coagulants and Anti-Coagulants
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: APIXABAN, ENOXAPARIN, RIVAROXABAN
Some products covered without a code (check the product listing): DABIGATRAN ETEXILATE, EDOXABAN, WARFARIN
20:12 Coagulants and Anti-Coagulants
· 11 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3), General benefit (8) · strengths: 15mg, 30mg, 60mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 20:12:04
20:12:16 Hemostatics
1 Indications
Fragmin (dalteparin sodium injection) is indicated for:
• Thromboprophylaxis in conjunction with surgery
• Treatment of acute deep venous thrombosis
• Unstable coronary artery disease (UCAD), i.e., unstable angina and non-Q-wave myocardial
infarction
• Prevention of clotting in the extracorporeal system during hemodialysis and hemofiltration in
connection with acute renal failure or chronic renal insufficiency
• Extended treatment of symptomatic venous thromboembolism (VTE) to prevent recurrence of
venous thromboembolism in patients with cancer
• Reduction of deep vein thrombosis (DVT) in hospitalized patients with severely restricted mobility
during acute illness. Decreased mortality due to thromboembolic events and complications has not
been demonstrated.
1.1 Pediatrics
Pediatrics (2 weeks – 18 years): Health Canada has not authorized an indication for pediatric use.
There is limited safety and efficacy information on the use of dalteparin in pediatric patients (see
Monitoring and Laboratory Tests, 7.1.3 Pediatrics, and Use in Pediatrics (2 weeks – 18 years)).
1.2 Geriatrics
Geriatrics: Elderly pat…
https://pdf.hres.ca/dpd_pm/00083068.PDF
PM date: not printed or not captured
Source product: FRAGMIN; DIN 02132621; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Prepare an Exceptional Access request
SADIE has its own form for many drugs; this checklist prepares the answers; the ministry decides. Open SADIE
Use this text in SADIE’s free-text fields or read from it on a Telephone Request Service call. Review marks do not indicate eligibility. Evidence stays in this page until you copy it; nothing entered here is sent or saved. Do not enter patient identifiers.
EAP Telephone Request Service: The TRS can be accessed by calling toll-free at 1-866-811-9893 or 416-327-8109 (Toronto area) between 8:30 a.m. and 5:00 p.m. Monday through Friday (except holidays) and selecting the TRS option. Source; updated September 15, 2026
Posted turnaround and Telephone Request Service scope
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
Dalteparin
Brand(s): Fragmin
DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products
For peri-operative bridging for patients who require long-term warfarin therapy and must
temporarily discontinue it before and after surgery, and who are at moderate- to high-risk
for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the date
of surgery plus up to 7 days after surgery.
For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on the
day of surgery.
For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or risk
factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days
For extended treatment of symptomatic acute venous thromboembolism (VTE) in
patients with cancer for whom warfarin treatment is not appropriate on a case-by-case
basis.
Standard Approval Duration: 6 months
28
Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.
Dalteparin (Fragmin)
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Prepare answers: See the ministry wording below; no separate indication heading is held.
1. For peri-operative bridging for patients who require long-term warfarin therapy and
must temporarily discontinue it before and after surgery, and who are at moderate- to
high-risk for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the
date of surgery plus up to 7 days after the date of hospital discharge
2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on
the day of surgery
3. For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or
risk factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days.
4. For extended treatment of symptomatic acute venous thromboembolism (VTE)
in patients with cancer, who cannot use warfarin.
Standard Approval Duration: As requested up to 6 months
469
Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.